
Regeneron COVID-19 antibody cocktail helps prevent symptomatic disease in study
Fox News
A monoclonal antibody cocktail developed by Regeneron and Roche dropped the risk of symptomatic COVID-19 by up to 76% after three days for recently infected individuals not yet experiencing symptoms, according to a press release posted Monday.
The currently authorized dosage is 1,200 mg of casirivimab and 1,200 mg of imdevimab administered together as a single infusion within 10 days of symptom onset. The results announced Monday drew from a Phase 3 study involving 204 individuals who were randomly assigned to receive the drug via 1,200 mg injection or placebo.More Related News

Students return to Brown University amid questions over security policies that enabled mass shooting
Brown University shooting survivors return to campus as students voice safety concerns following deadly attack by Claudio Manuel Neves-Valente that killed two students.












